Toxicokinetics of nortriptyline and amitriptyline: Two case reports

Therapeutic Drug Monitoring

Volumn 25, Issue 2, 2003, Pages 248-251

  Franssen, E J F ^a   Kunst, P W A ^b   Bet, P M ^a   Strack van Schijndel, R J M ^b   Van Loenen, A C ^a   Wilhelm, A J ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Critical care; Intoxication; Overdose; Prognostic factors; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; NORTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CASE REPORT; COMA; DEPRESSION; DRUG BLOOD LEVEL; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; INTENSIVE CARE; INTOXICATION; MALE; METABOLITE; PRIORITY JOURNAL; PROGNOSIS; QRS COMPLEX; STEREOCHEMISTRY; SURVIVAL; TOXICOKINETICS;

ADULT; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; IMMUNOASSAY; MIDDLE AGED; NORTRIPTYLINE; OVERDOSE;

EID: 0037380731     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200304000-00018     Document Type: Article

References (14)

1. Ellenhorn's medical toxicology. 2nd ed. Baltimore: Williams & Wilkins, 1997.
2. Hulten B-A, Adams R, Askenasi R, et al. Predicting severity of tricyclic antidepressant overdose. Clin Toxicol 1992;30:161-70.
3. Hulten B-A, Heath A, Knudsen K, et al. Severe amitriptyline overdose: relationship between toxicokinetics and toxicodynamics. Clin Toxicol 1992;30:171-9.
4. Bertilsson L, Alexanderson B. Stereoselective hydroxylation of nortriptyline in man in relation to interindividual differences in its steady-state plasma. Eur J Clin Pharmacol 1972;4:201-5.
5. Bertilsson L, Eichelbaum M, Mellström B, et al. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980;27:1673-7.
6. Mellström B, Bertilsson L, Sawe J, et al. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981;30:189-93.
7. Gram LF, Pedersen OL, Kristensen CB, et al. Drug level monitoring in psychopharmacology: usefulness and clinical problems, with special reference to tricyclic antidepressants. Ther Drug Monit 1982;4:17-25.
8. Bertilsson L, Mellström B, Sjöqvist F. Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. Life Sci 1979;25:1285-92.
9. Uges DRA, Noten JBGM. The serum concentration of tricyclic antidepressants. In: Merkus FWHM, ed. The serum concentration of drugs. Clinical relevance, theory and practice. Proceedings of a symposium on the occasion of the 50th anniversary of the Netherlands Association of Hospital Pharmacists. Amsterdam: Excerpta Medica, 1980:114-24.
10. Dahl-Puustinen, Perry TL Jr, Dumont E, et al. Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. Clin Pharmacol Ther 1989;45:650-6.
11. Nordin C, Bertilsson L. Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline. Clin Pharmacokinet 1995;28:26-40.
12. Nordin C, Bertilsson L, Siwers B. CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite. Br J Clin Pharmacol 1985;20:411-3.
13. Nordin C, Bertilsson L, Dahl ML, et al. Treatment of depression with E-10-hydroxynortriptyline - a pilot study on biochemical effects and pharmacokinetics. Psychopharmacology (Berl) 1991; 103:287-90.
14. Otani K, Kaneko S, Bertilsson L. Studies on active transport of (E)-10-hydroxynortriptyline in the kidney and brain of rats: effects of propranolol and quinidine. Pharmacol Toxicol 1991;68:380-3.